Developing Personalized Treatment Strategies for Patients With Multiple Myeloma
Advances in genetic and molecular assessment strategies have led to improved outcomes for patients with multiple myeloma.
All articles by John Schieszer, MA
New B Progenitor Acute Lymphoblastic Leukemia Subtypes Identified
The identification of 8 new subtypes of B progenitor acute lymphoblastic leukemia may guide the diagnosis and development of more effective targeted therapies.
A Serological Tool to Phenotypically Characterize Primary Antiphospholipid Syndrome
Researchers assessed the prevalence of various antiphosphatidylserine/prothrombin antibodies in patients with primary antiphospholipid syndrome.
Chemotherapy Intensification May Not Improve Outcomes in Patients With B Cell Acute Lymphoblastic Leukemia
Researchers assessed the influence of cyclophosphamide plus etoposide on disease-free survival in patients with B-cell acute lymphoblastic leukemia.
A Novel Relapse Risk Stratification Model for Patients With Diffuse Large B-Cell Lymphoma
Researchers combined the International Prognostic Index with cell-of-origin subtype to identify patients at high risk for central nervous system relapse.
Luspatercept May Improve Hemoglobin Levels in Patients With Beta Thalassemia
A high percentage of patients with beta thalassemia demonstrated an increase in hemoglobin levels after receiving luspatercept.
Tranexamic Acid Concentrations Required for Fibrinolysis Inhibition
The need for tranexamic acid to be administered intravenously creates a barrier to rapid treatment of patients with fibrinolysis.
Venetoclax, Hypomethylating Agents Are Changing the Treatment Landscape for Acute Myeloid Leukemia
Venetoclax and hypomethylating agents, which both demonstrate single agent activity in acute myeloid leukemia, appear to be more effective when used together.
Risk Factors for Chemotherapy-Induced Nausea in Pediatric Patients
Nonwhite race, poor acute phase nausea control, and treatment with cisplatin were all associated with higher self-reported nausea severity scores.
Complement C1s Inhibition May Prevent Hemolysis in Cold Agglutinin Disease
Patients who received sutimlimab experienced meaningful increases in hemoglobin levels and normalization of bilirubin levels.
- Loading...
Loading...
Next post in Anemia
Loading... 
Loading...